Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/jptcp.v29i03.2677

A REVIEW FOR MEDICAL AND DENTAL PROFESSIONALS CONCERNING THE NEW MONKEY POX WARNING

Dr Simrat Bhullar[1], Dr Harnoor Singh[2], Dr Reshma Dodwad[3], Dr Navpreet Singh[4], Dr Vithal Kumar Malleshi Betigeri[5], Dr Harnoor Singh Sandhu[6], Dr Avineet Kaur[7]*

[1]MBBS, Junior Resident, Department of Orthopedics Gian Sagar Medical Hospital Banur, Rajpura (Punjab) (India)
[2]MBBS, Junior Resident, Department of Medicine Gian Sagar Medical Hospital Banur, Rajpura (Punjab) (India)
[3]MDS, Reader, Department of Pedodontics and Preventive dentistry Krishnadevaraya College of Dental Sciences, Banglore (Karnataka) (India)
[4]MD, Assistant Professor, Department of Medicine Gian Sagar Medical Hospital Banur, Rajpura (Punjab) (India)
[5]M.ch Director, Professor, Department of Cardiothoracic and Vascular Surgery (CTVS) 1-Jwahar Lal Nehru Marg, Govind Ballabh Pant Institute of Postgraduate Medical Education Research, New Delhi (India)
[6]MBBS, Incharge Emergency Medicine, Department of Emergency Gian Sagar Medical Hospital Banur, Rajpura (Punjab) (India)
[7]MDS, Associate Professor, Department of Periodontology and Oral Implantology Swami Devi Dyal Dental College and Hospital Golpura, Barwala (Haryana) Email: Kauravineet85@gmail.com

***Corresponding Author:** Dr Avineet Kaur
*MDS, Associate Professor, Department of Periodontology and Oral Implantology Swami Devi Dyal Dental College and Hospital Golpura, Barwala (Haryana) Email: Kauravineet85@gmail.com

Abstract
MPXV, or monkey pox virus, is a associated with Poxviridae family and the Ortho poxvirus genus. Only two different species of wild animals— just like a a rope squirrel located in the Democratic Republic of the Congo and a sooty mangabey in Ivory Coast—have had a virus isolated from them. Protection against monkey pox infection after receiving the smallpox vaccine was calculated to be around 85%. Since smallpox was finally eradicated in 1980, widespread vaccination campaigns have tapered down. That opened the door for monkey pox to be considered as a bioterror threat.

Keywords: Monkey pox, Diagnosis, Africa, and the United States

Introduction

Monkey pox virus (MPXV), is a member of the Ortho pox virus genus which is in the Poxviridae family, is the causative agent of this newly recognized zoonotic illness. MPXV is one of four species of Ortho pox virus that may cause disease in humans; the others being variola virus (which caused smallpox but has since been wiped from the natural world), cowpox virus, and vaccinia virus. The true host of monkey pox has not been identified, despite the fact that it can infect a broad variety of mammals. To date, this virus has only been cut off two times from wild animals, out of which once it has been derieved from a rope squirrel in the Democratic Republic of the Congo

(DRC) and another time from a sooty mangabey in Ivory Coast. It is hypothesized that transmission takes place by contact with lesion exudate or crust material, or through saliva/respiratory excretions. Exposure to viruses may also occur through feces. In terms of symptoms, monkey pox is very similar to smallpox, with the exception of an early arrival of fever and lymph node enlargement that sets MPX apart from smallpox. Rash symptoms, including fever, lymphadenopathy, and the development of lesions, typically begin 1-3 days after the onset of systemic symptoms. Their typical pattern of spread is at the periphery, but in extreme cases they may spread everywhere. It may take up to four weeks for the lesion to desquamate once the infection has cleared. Secondary bacterial infections, bronchopneumonia, sepsis, dehydration, respiratory distress, gastrointestinal involvement, encephalitis, and corneal infection leading to vision loss are all probable consequences. Supportive care and symptomatic treatment are used to manage people with monkey pox virus infections because there is presently no cure.[1] Case ascertainment bias can cause a significant amount of variation in reported death rates. Outbreaks in the Congo Basin have had documented case fatality rates between 1 and 10 percent, and the viral lineage that is circulating in this area is thought to be more dangerous than others. Recent outbreaks in Nigeria have been traced to the west African lineage, which is linked with a persistently lower overall fatality time of less than 3%. 6,8 Most of the recorded deaths up to this point have been of children below the age of 5 and people living with HIV.[2] There has been an increase in the quantity of established and supposed cases infected with monkey pox infection in a few countries across North America and Europe over the past few weeks. Among these are the continents of Canada, the United States, the United Kingdom, Italy, Germany, Portugal, Belgium, France, Sweden, and even Australia. Immunization efforts in the past have shown with the results that the smallpox vaccine is about 85% effective in preventing monkey pox. The reduction in routine vaccination programs that followed the 1980 eradication of smallpox allowed monkey pox to re-emerge as a potential hazard.[3] While brincidofovir and tecovirimat, both of which treat smallpox, are not yet allowed for use in humans, they have been approved in the United States in case of a bioterrorist attack. Both medications have shown efficiency against various orthopoxviruses (with monkey pox) in animal models, but human efficacy trials have not yet been conducted. A number of cases of tecovirimat being used for compassionate purposes to treat severe cases of vaccinia and cowpox have been reported, and so far there have been no reported adverse effects. Because of the prevalence of monkey pox in the Central African Republic, a tecovirimat extended access programme is now being developed.[2]

Historical Background [4]

A case of monkey pox (MPX) contracted by a voyager from Nigeria was confirmed in the United Kingdom that is on **May 7, 2022.** The patient reported becoming ill with a rash-like condition and on **April 29, 2022,** and then traveling all the way from Lagos to London on May 3 and 4. The Rare and Imported Pathogens Laboratory United Kingdom Health Security Agency (UKHSA) verified the diagnosis on May 6 using monkey pox virus (MPXV) PCR on a vesicular swab.

Two further MPX cases were brought up the United Kingdom on **May 13, 2022,** both were related to the single imported case from Nigeria that had been reported on May 7. PCR testing on swabs taken from vesicles verified the instances. Thirdly, another family member had a rash before but was completely fine now. No one in this grouping had any relevant travel experience or knew anyone else who did.

Four further PCR-confirmed cases of MPX were reported in the United Kingdom that is on **May 15th,2022.** There is no evidence to suggest that the imported case from Nigeria (reported on May 7) or the family cluster are connected to any of these other instances (notified on 13 May). Patients in all four cases presented with a vesicular rash and were classified as men who had sex with men (MSM). Patients in this group were discovered due to their presence at GUM clinics. In the UK, these cases are being handled by specialized clinics for treating infectious infections with potentially devastating outcomes.

As of the **18th of May 2022,** two other cases (both MSM) had been reported, one in London and one in the South-East of the country.
The UK Health Security Agency (UKHSA) has observed established 20 cases of MPX in England as of **May 20.** Eleven more cases were reported on May 20. The MPXV West African clade is accountable for all cases recorded in the United Kingdom.
More confirmed or suspected instances were reported by many EU/EEA Member States beginning on May 18:

On May 18th, **Portugal** announced 14 confirmed cases of MPXV in the Lisbon and Tagus River Valley Area, confirmed by real-time polymerase chain reaction. All patients were male and presented with fever, rash (some ulcerative), muscle weakness, and fatigue. All patients were able to avoid hospitalization. It was reported that there were 23 verified cases as of May 20; nine further cases were confirmed on that day. Two samples were found to belong to the west African clade.
Men accounted for all of the 19 suspected cases and 7 confirmed cases of MPX that were reported in **Spain** on May 19. On May 20th, officials announced 16 more verified cases. Seven additional confirmed cases and 39 additional suspected cases were reported on May 22.

A guy with known ties to Lisbon, Portugal, was proven to have the disease in **Belgium** on May 19. On May 20th, it was discovered that his partner had also been experiencing these symptoms. To date (May 22), four verified cases have been reported.

The first case in **Germany** was confirmed on May 19 in a guy who had previously visited Spain and Portugal. Two additional confirmed instances were announced on May 20.
France confirmed its first case on May 20; three other suspected cases are still being investigated.
On May 20th, **Italy** announced that a guy who had recently returned from Spain had contracted MPX and was hospitalized. There were two further confirmed cases that were announced on May 21.
As of May 18th, **Sweden** had confirmed a male case.
One confirmed case, a male with known connections to Belgium, was reported in the **Netherlands** on May 20.
The initial verified case was reported on May 22 in **Austria.**
In nine EU/EEA Member States, 67 confirmed cases and at least 42 probable cases had been recorded as of May 23.

Epidemology
African monkeypox.[5]Having been spread to humans through close contact with sick monkeys, monkey pox has likely been a problem in sub-Saharan Africa for around thousands of years. Nobody knows where MPXV comes from. There is evidence, however, that monkeys are only accidental hosts, much like humans, and that the pool is probable to be one of many rodent or squirrel species living in the derived forest of central Africa. While smallpox had been eradicated from Zaire which is (present-day Democratic Republic of the Congo [DRC]), the persistence of a disease with similar symptoms in rural regions did not prompt its identification as monkey pox until 1970. Although the global eradication campaign's widespread vaccination in central Africa likely resulted in a temporary decrease in the disease's incidence, the lack of immunity in the age group born since then and the amplified addiction on hunting for foodstuff in areas distressed by civil war have led to the reemergence of the illness.
Spread of monkey pox in the United States.[5] MPXV was discovered to be the culprit for an occurrence of illness in the Midwest of the United States back summer of 2003. The appearance of MPXV in the Americas marked its first occurrence in that region. During an outbreak, 37 human cases were confirmed by a laboratory out of a total of 72. Since most of the prairie dogs (Cynomys

species) in the United States were kept alongside rodents brought from Ghana in western Africa, it was thought that the prairie dogs were the primary source of the outbreak.
Avoid contact with domesticated prairie dogs as a source of infection. Although it believed that the virus was spread through making a contact with an infected prairie dog, two of the patients had straight touch with their sick children through caring for them.

The authors of an epidemiological modeling study found that the R0 value of monkey pox, also known as the reproduction ratio or the degree of transmissibility of the disease, ranges starting from 1.10 to 2.40 in nations with low levels of contact to Ortho pox virus species. When applied to hypothetical scenarios including imported human or animal cases, this value strongly predicts that an epidemic of monkey pox is impending. As was indicated before, the observed R0 indicates that each infected person can potentially infect one to two others. The contagious nature of the virus makes it critical for an infected person to isolate and avoid contact with others. There have been 5,783 established cases of monkey pox dated on July 1, 2022, in 52 nations, according to the Centers for Disease Control and Prevention (CDC). At present, Europe and additional areas of the western hemisphere are seeing a disproportionate share of monkey pox cases. According to recent data, the United Kingdom has the highest prevalence rate among European countries. Numerous of the currently established cases of monkey pox are found in people below the age of 40, with the median age being just 31. Because this group was born following the smallpox vaccination program ended, they have no cross-protective immunity. In addition, males are more likely to contract monkey pox than females, though the reason for this disparity is unclear.[6]

Etiology[7]

The Monkey pox virus is associated with genus Orthopoxvirus and the species Monkey poxvirus. The monkey pox virus is visible as a relatively big particle in electron micrographs (200-250 nanometers). Poxviruses have a lipoprotein sheath around their brick-shaped, double-stranded DNA genome. Poxviruses have all of the proteins necessary for replication, transcription, assembly, and egress encoded in the genome, albeit they must use host ribosomes for mRNA translation.

Transmission Routes



Differential Diagnosis[7]

• Smallpox
Worldwide Immunization Program
• Zoster disseminatus
• Chickenpox
Herpes simplex dermatitis
Spreading herpes simplex virus
• Syphilis
•Rickettsialpox
• Yaws
• Measles
• Scabies
• Skin diseases caused by bacteria
The Drug-Induced Eruption

Prognosis[7]

The monkey pox virus can be divided into two groups known as clades. With a case fatality rate of less than 1%, the West African clade has a better outlook. A case fatality rate of up to 11% in unvaccinated youngsters has been reported for the Central Basin clade (Central African clade), which is additional dangerous. Patients usually make a full recovery within four weeks of symptom onset, with the exception of permanent scarring and skin discoloration.

Western and Central Europe of Monkeypox[8]

The monkey pox viruses in West Africa and in Central Africa belong to separate phylogenetic clades. Evidence from the West African clade epidemic in the United States in 2003 revealed that illness severity also varied across clades. Liberia, Nigeria, Sierra Leone, and Côte d'Ivoire each reported less than ten cases of West African monkey pox between 1970 and 2005, and the United States experienced an outbreak with 47 confirmed cases. The severity of symptoms in humans and nonhuman primates infected with West African monkey pox is often lower than in other regions of the world. There were a lot of hospitalizations and serious illness in the US outbreak, but no deaths. A list of potential genes that may be occupied in the distinguishing clade pathogenicity was uncovered by comparing the genomes of Central and West African strains. These ORFs are thought to play a role in virulence, host range expansion, immune system evasion, or other viral adaptations. Human cells derieved from monkey pox patients are resistant for T-cell receptor-mediated T-cell activation and the subsequent generation of inflammatory cytokines. These results point to the leeway that monkey pox can result in antagonistic modulator of host T-cell responses. Central African monkey pox virus has been found to have multiple potential mechanisms of immune evasion. An major immune modifying component causative agent to the enhanced virulence of Central African strains has been linked to the presence of a gene that inhibits complement enzymes in the monkey pox virus but is missing in West African strains. Furthermore, Central African monkey pox strains selectively down regulate host responses, together with apoptosis in the host, in comparison to West African viruses. The observed pathogenicity variations may involve many loci. In addition, studies of transcription have revealed that Central African monkey pox appeared to selectively repress transcription of genes implicated during infection in hosts compromising the immunity. It will need a complex effort to learn the full scope of these viruses' potential consequences.

Diagnosis[9]

The continuing 2022 outburst highlights the significance of maintaining a high index of doubt for monkey pox infection and mindful of frequently atypical presentations of the infection. Clinicians who suspect monkey pox should inquire about recent travel, sexual activity, and close contacts with other patients who may have been exposed to the virus. Sleeping together, sharing utensils while

eating or drinking, sharing a home, etc. are all examples of intimate contact behaviors. Deficient of a voyage history or a particular recognized close contact with a rash or with a supposed or established monkey pox infection should not regulate out the possibility of this diagnosis. The skin should also be examined carefully. Extraction of a lesion sample for molecular examination by PCR is the most excellent method for diagnosing a cases with a supposed active monkey pox infection. Lesions should be unroofed to appropriately capture virus-containing fluids, and ideally more than one specimen should be acquired from two independent lesions on various areas of the body. While some labs are operational to provide direct PCR testing for OPXV while others MPXV, which then needs to be definite by testing for MPXV at a mentioned lab. It is reasonable to assume that a positive OPXV test indicates monkey pox infection in the perspective of the present outburst, even before findings from confirmatory testing are available. It is preferable to coordinate testing plans with public health officials before collecting specimens.

Virus strains for further characterization can be grown in cells, however this can be done in standard biosafety level 3 mentioned laboratories. Serological testing has been the possible aid in epidemiological studies, the retrospective diagnosis of prior infections, and the analysis of late clinical symptoms such as encephalitis. Although populace who have already been vaccinated against smallpox may have an adverse reaction to MPXV serology, this is not a problem for those who have not been immunized.

Clinical Management[9]

Clinical management of a typical monkey pox illness focuses on providing comfort and relief. Maintaining a healthy fluid balance is an important part of providing comfort care (because of the opportunity of amplified insensible fluid losses from the skin, vomiting or diarrhea and decreased oral intake. In some cases, it could be necessary to resort actions such as hemodynamic support, respiratory assistance, supplementary oxygen, or to treat bacterial superinfections of skin lesions. Ocular infection/complication management, including corneal scarring and/or vision loss, has also been described in the situation of earlier OPXV infections as part of supportive care. Topical antibiotics, topical lubricants and possibly topical antivirals like trifluridine are all viable options to investigate here.

There are currently no treatments for monkey pox that are covered by the US Food and Drug Administration (FDA). However, brincidofovir (a lipid-conjugate prodrug of cidofovir), cidofovir and tecovirimat are all effective antiviral medicines against MPXV. Vaccinia immune globulin intravenous (VIGIV) is a drug that the FDA has previously green-lighted for use in treating vaccinia vaccination side effects such as severe generalized vaccinia and progressive vaccinia. The CDC maintains Expanded Access Investigational New Drug (EA-IND) protocols for the management of OPXV infections from the Strategic National Stockpile with the drugs cidofovir, tecovirimat and VIGIV. The Centers for Disease Control and Prevention (CDC) processes requests from state and territorial health agencies in the United States for permission to these drugs.

Immunization[9]

OPXV infection has been shown to provide cross-protection against other orthomyxoviruses. Unfortunately, there are currently no vaccines available to prevent monkey pox. The vaccinations against MPXV that are currently under consideration (vaccines based on the Vaccinia virus) were initially intended to combat smallpox.

Discussion

Thirty years after smallpox vaccination efforts end in the Democratic Republic of the Congo, **Rimoin A W et al. (2010)[10]**found a dramatic increase in the prevalence of human monkey pox. Cumulative Active surveillance data from the same locations between 1981 and 1986 was compared to prevalence (per 10,000 population) and significant drivers of infection. Laboratory confirmation of 760 cases of human monkey pox was obtained in the health zones that participated between 2005

and 2007. The overall cumulative incidence rate each year was 5.53 per 10,000 (2.18–14.42). Living in a wooded region, being male, being under the age of 15, and having never been vaccinated against smallpox all enhanced the likelihood of contracting the disease. The probability of getting monkey pox was reduced by 5.2-fold among vaccinated individuals compared to those who hadn't been (0.78 vs. 4.05 per 10,000). Analyzing 1980s active scrutinized data from the identical health zone (0.72 A comparison of the human monkey pox incidence rates in 1996-97 (0.00 per 10,000) and 2006-07 (14.42 per 10,000) implies a 20-fold rise. Human monkey pox has reemerged in rural DRC 30 years after large immunization operations against small pox were abandoned. Epidemiological and surveillance improvements in order to assess the public health burden and devise methods to lessen the likelihood of further infection, research is required.

Outside of the endemic areas in Africa, it was first documented in **2022 by Thornhill J.P. et al.**[11] There are currently cases happening all across the world. Almost every aspect of this sickness is unknown to us: how it is spread, what causes it, how it manifests in the body, and what happens to those who contract it. This case series shows that there is a wide range of dermatological and systemic manifestations of monkey pox. The need for quick case identification and diagnosis is highlighted by the immediate discovery of patients outside of locations where monkey pox has conventionally been endemic.

For the year **2022, Sherwat A., et al**.[12] The current situation presents the same dilemma: how to administer compassionate right use to a drug whose safety and efficacy in humans have not been recognized, in this case tecovirimat, accessible for clinical use below an expanded-access protocol that may theoretically speed resolution of monkey pox illness and progress outcomes. Since both smallpox and monkey pox are caused by the identical genus of viruses, it is significant to understand the foundation for tecovirimat's support by the U.S. Food and Drug Administration (FDA) for the treatment of smallpox and the knowledge gaps that stay in order to determine what role it might participate in response to the monkey pox outbreak. The antiviral medication tecovirimat under a rule commonly referred to as the "Animal Rule," which was authorized for use in the treatment of smallpox. When human efficacy studies are not possible or ethical, and field trials cannot be conducted to test a drug or biologic product's efficacy, this route can be used to approve the drug for use in treating serious or life-threatening conditions. The Animal Rule requires that research in animal models be both sufficient and well-controlled in order to prove efficacy. sickness or condition in humans; proper human safety testing is required. Animal experiments with closely similar ortho pox viruses (to smallpox) demonstrated tecovirimat's efficacy, and the medicine was eventually licensed for use in humans. Animals that aren't humans, such monkeys infected with the monkey pox virus or rabbits infected with the rabbit pox virus. In these experiments, animals given tecovirimat had a far higher survival rate than those given a placebo between the participants who were given a placebo and the others. Adverse reactions in healthy volunteers who were given tecovirimat were investigated to determine the drug's human safety. Dosing for the management of smallpox in humans with tecovirimat was determined by comparing plasma concentrations of doses proved to be fully valuable next to monkey pox and rabbit pox in animal models and test it on healthy humans. Outcomes from research in animals and hale and hearty people were also used to determine the optimal therapy duration for humans.

Conclusion

MPXV, or monkey pox virus, is a member of the Poxviridae family and the Orthopoxvirus genus. The rope squirrel and the sooty mangabey are the only two wild animals to have their virus isolated. Protection against monkey pox infection after receiving the smallpox vaccine was calculated to be around 85%. Since smallpox was eradicated in 1980, systematic vaccination programs have decreased, allowing monkey pox to reappear as a disease that could pose a concern. Two instances in the United Kingdom have been linked to the West African lineage of MPXV. As of May 23rd, 2022, nine EU/EEA Member States had reported a total of 67 confirmed cases, with an additional

42 instances being investigated as possible cases. The reproduction ratio (R0) for monkey pox is 1.10-2.40. The viral transmission rate, R0, measures how easily the virus can be spread. This raises concerns that an imported human or animal case could quickly spread into a full-blown epidemic.

References

1. Sklenovská N, Van Ranst M. Emergence of Monkeypoxas the Most Important Orthopoxvirus Infection in Humans. Frontiers in Public Health. 2018;6.
2. Adler H, Gould S, Hine P. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet. 2022 Aug.; 22: 1153-62.
3. Medhi B. Monkeypox infection: A quick glance. Indian Journal of Pharmacology. 2022;54(3): 161-4.
4. Monkeypox multi-country outbreak [Internet]. [cited 2022Aug.25]. Available from: https://www.ecdc.europa.eu/en/monkeypox-outbreak
5. Nalca A, Rimoin AW, Bavari S. Reemergence of Monkey pox: Prevalence, Diagnostics, and Countermeasures Aysegul Nalca. Clinical Infectious Diseases . 2005;41.
6. Kaler J, Hussain A, Flores G, Kheiri S, Desrosiers D. Monkey pox: A Comprehensive Review of Transmission, Pathogenesis, and Manifestation. Cureus. 2022;.
7. Moore MJ, Rathish B, Zahra F. Monkey pox. [Updated 2022 Jul 16]. In: StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574519/
8. Mc Collum AM, Damon IK. Human Monkey pox. Emerging Infections. 2014 Jan.;58: 260-7.
9. Titanji BK, Tegomoh B, Nematollahi S, Konomos M, Kulkarni PA. Monkeypox: A Contemporary Review for Healthcare Professionals. Open Forum Infectious Diseases. 2022;9 (7).
10. Rimoin AW, Mulembakani PM, Johnston SC, Lloyd Smith JO, Kisalu NK, Kinkela TL, Blumberg S, Thomassen HA, Pike BL, Fair JN, Wolfe ND, Shongo RL, Graham BS, Formenty P, Okitolonda E, Hensley LE, Meyer H, Wright LL, Muyembe J-J. Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences. 2010;107(37):16262-7.
11. Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen A-BE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM. Monkey pox Virus Infection in Humans across 16 Countries — April–June 2022. New England Journal of Medicine. 2022;387(8):679-91.
12. Sherwat A, Brooks JT, Birnkrant D, Kim P. Tecovirimat and the Treatment of Monkey pox — Past, Present, and Future Considerations. New England Journal of Medicine.2022;387(7):579-81.